According to study, China’s leading COVID-19 vaccine candidate have shown positive results. It also elicited immune response in a small early-phase human trial. The results of the Chinese vaccine tested on people aged 18 to 80 have shown good results. In these tests, the vaccine has been found to be safe and has not caused any harm, rather it has helped in the formation of antibodies.
According to the Lancet Journal report, the Chinese vaccine BBIBP-CorV is absolutely safe and capable of producing antibodies, but that study only tested vaccines on people under 60 years of age.
Vaccine trials included participants between the ages of 18 and 80:
This latest study, published in The Lancet Infectious Diseases Journal, reported that trials in this vaccine included participants between the ages of 18 and 80 and found antibodies responses were induced in all recipients. According to the study, the rate of making antibodies against this vaccine was higher in people between 18 and 59 years than in people older than 60. Antibodies took 42 days to form in people over the age of 60 years, whereas in 18 to 59 years participants developed antibodies in 28 days.
Protecting older people is a key aim of a successful COVID-19 vaccine: Xiaoming Yang
Chinese author Xiaoming Yang of the Beijing Institute of Biological Products Co. Ltd. said that protecting older people is a key aim of a successful COVID-19 vaccine, as this age group is at greater risk of severe illness from the disease. However, vaccines are sometimes less effective in this group because the immune system weakens with age. It is therefore encouraging to see that BBIBP-CorV induces antibody responses in people aged 60 and older. We believe this justifies further investigation.
He said, ‘Our findings indicate that a booster shot is necessary to achieve the greatest antibody responses against SARS-CoV-2. It could be important for protection. This provides useful information for a phase 3 trial.’